Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2020 Oct 27;11:615275. doi: 10.3389/fimmu.2020.615275

Corrigendum: Interferon-α2b Treatment for COVID-19

Qiong Zhou 1, Virginia Chen 2, Casey P Shannon 2, Xiao-Shan Wei 1, Xuan Xiang 1, Xu Wang 1, Zi-Hao Wang 1, Scott J Tebbutt 2,3, Tobias R Kollmann 4, Eleanor N Fish 5,*
PMCID: PMC7653513  PMID: 33193462

Error in Figure/Table

In the original article, there was a mistake in Table 1 as published. For ‘Days from symptom onset to treatment,’ the IFN+ARB and ARB values were inadvertently switched. IFN+ARB should be 8.0 [5.0,11.0] and ARB should be 17.0 [10.0, 22.0]. The corrected Table 1 appears below.

Table 1.

Demographics and clinical characteristics of patient cohort.

IFN n = 7 IFN+ARB n = 46 ARBn = 24 p-value
Age, yrs 41.3 (27–68) 40.4 (25–80) 64.5 (37–73) <0.001
Male (%)
Female (%)
0 (0.0%)
7 (100%)
20 (43.5%)
26 (56.5%)
11 (45.8%)
13 (54.2%)
0.076
Comorbidities (%) a 14.3% 15.2% 54.2% 0.002
Initial symptoms
 Fever (%) 57.1% 58.7% 70.8% 0.632
 Cough (%) 42.9% 50.0% 54.2% 0.888
 Fatigue (%) 14.3% 23.9% 37.5% 0.422
 Myalgia (%) 14.3% 13.0% 29.2% 0.228
 Headache (%) 14.3% 6.52% 4.17% 0.590
 Pharyngalgia (%) 0.00% 13.0% 8.33% 0.742
 Chest pain (%) 14.3% 6.52% 20.8% 0.134
 Expectoration (%) 14.3% 8.70% 20.8% 0.281
 Nausea (%) 0.00% 0.00% 4.17% 0.403
 Diarrhea (%) 14.3% 4.35% 20.8% 0.081
Days from symptom onset to hospital admission b 8.0
[5.5, 15.5]
6.5
[3.0, 10.0]
10.0
[4.5, 19.5]
0.087
Days from symptom onset to 1st treatment b 8.0
[6.5, 16.00]
8.0
[5.25, 11.0]
17.0
[10.0, 22.0]
<0.001
a

Hypertension, diabetes, COPD, chronic bronchitis, heart disease, cancer.

b

Median and interquartile range [Q1, Q3] are reported.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES